Resolved hepatitis B is associated with higher reactivation risk than chronic infection after chemoembolization for hepatocellular carcinoma

doi:10.3748/wjg.120320

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 39

This Article

(5)

(7)

(0)

(11)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Oct 21, 2026; 32(39): 120320
Published online Oct 21, 2026. doi: 10.3748/wjg.120320

Full Size Figure Download Figure

Figure 2 Forest plot of multivariable Cox regression analysis for hepatitis B virus reactivation. Hazard ratios and 95% confidence intervals are shown for variables included in the final multivariable model. Variables with P < 0.05 in the univariable analysis were entered into the multivariable model. The vertical dashed line indicates hazard ratio = 1 (no effect). Orange denotes statistical significance (P < 0.05). HBV: Hepatitis B virus; AFP: Alpha-fetoprotein; CI: Confidence interval.

Citation: Kim DY, Jeong J, Hong JP, Lee JS, Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Kim DY, Lee HW. Resolved hepatitis B is associated with higher reactivation risk than chronic infection after chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2026; 32(39): 120320
URL: https://www.wjgnet.com/1007-9327/full/v32/i39/120320.htm
DOI: https://dx.doi.org/10.3748/wjg.120320

Kim DY, Jeong J, Hong JP, Lee JS, Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Kim DY, Lee HW. Resolved hepatitis B is associated with higher reactivation risk than chronic infection after chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2026; 32(39): 120320 [DOI: 10.3748/wjg.120320]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.